… trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart
disease or at high risk for coronary heart disease. Eligible patients who were taking a statin …

… safety study that showed anacetrapib, … anacetrapib demonstrates the greatest HDL-C–raising
and LDL-C– lowering potential of CETP inhibitors, and phase I and II trials with anacetrapib …

… reduction at 6 years was more than 50% greater than at the end of the treatment period. In …
the risk of death from coronary heart disease during extended follow-up. Importantly, no safety …

… the clinical efficacy and safety of anacetrapib (at a dose of 100 … patients with preexisting
atherosclerotic vascular disease who … , or diabetes with symptomatic coronary heart disease. Key …

… , aldosterone, and prespecified cardiovascular adjudicated events. The … safety parameters
after cessation of anacetrapib in the DEFINE study. Because a previous phase 2b anacetrapib …

… , or diabetes mellitus with other evidence of symptomatic coronary heart disease), had none
… efficacy and safety of anacetrapib among individuals at high risk for cardiovascular events …

… per their NCEP ATP III coronary heart disease risk category (ie, an … and safety/tolerability
profile of anacetrapib in patients with … of patients enrolled to determine the effects of anacetrapib …

… This study included a 12-week off-drug phase to assess the effects of anacetrapib on lipid/apolipoprotein
parameters and safety/tolerability following the cessation of treatment (ie, week …

… for torcetrapib (72%) 7 or anacetrapib (138%), 42 respectively. Low-density lipoprotein
cholesterol did not change in contrast to torcetrapib and anacetrapib which lower LDL-C by 25 …

… of cardiovascular disease. We aimed to investigate the safety and efficacy of anacetrapib,
a cholesteryl ester transfer protein inhibitor, in patients with heterozygous familial …